Alzheimer's disease is a complex condition that scientists are still trying to understand. One big challenge is figuring out how to spot it early. Thanks to modern technology, researchers can now look at the entire human genome using something called microarrays. This should make diagnosing Alzheime
The internet is full of dangers, and one of the scariest is the possibility of sensitive data being accidentally left open for anyone to find. This fear became a reality when a huge collection of 184 million records was found exposed online. This wasn't just any data; it included login details for b
Psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) are complex conditions. They affect many people. Yet, there is a gap in understanding how these conditions are treated in real-world settings. This is especially true for biologic and targeted synthetic disease-modifying anti-rheumatic
Wearable tech has made it possible to collect detailed health data from many people over long periods. This type of data is great for spotting differences between people and changes within the same person over time. Think about how your heart rate changes on weekends. It might go up or down based on
Healthcare spending is a big deal. It's not just about money. It's about how countries take care of their people. A recent study dug deep into this topic. It looked at 37 wealthy nations over 12 years. The goal? To find out what makes healthcare spending tick. The study used a fancy method called f
The number of immigrants in Canada is growing. This growth is putting pressure on the country's cancer treatment system. To understand this better, it's important to look at cancer rates among immigrants. This data can help plan for future cancer services and ease the strain on the healthcare system
In the world of cancer treatment, making the right call on which drugs to approve is a big deal. The National Institute for Health and Care Excellence, or NICE, is at the heart of this process. They often rely on a measure called overall survival, which tracks how long patients live after treatment.
A major shift is happening in the world of genetic data. Regeneron, a big name in biotechnology, is stepping in to buy 23andMe, a company known for its DNA testing kits. The price tag? A cool $256 million. This move comes as 23andMe faces bankruptcy, but Regeneron has plans to keep the company runni
The sun has always been a powerful force, but 14, 300 years ago, it unleashed a solar storm that was off the charts. This storm was so intense that it left a mark on Earth's atmosphere that scientists could still detect today. It was so powerful that it was more than 500 times stronger than the most
One major player in the genetic testing world, 23andMe, has made a significant move. They sold their massive genetic data bank to a drug company, Regeneron Pharmaceuticals. The deal is worth 256 million dollars. This data bank holds genetic information from around 15 million people. The sale happene
